ClinicalTrials.gg
Not yet recruitingNCT07862595Updated Nov 6, 2026

A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)

A Phase 2 interventional study of MK-6916 and Hydrocodone/acetaminophen (HB/APAP) in Pain Management, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Updated Nov 6, 2026First site in United StatesStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Researchers are looking for new treatments for pain. While there are many approved treatments for pain, the treatments do not work well for everyone. People can also become addicted to certain pain medicines. Researchers designed a trial medicine called MK-6916 to treat pain.

The goal of the trial is to learn if at least 1 dose of MK-6916 works better than placebo to lessen pain. A placebo looks like the trial medicine but has no trial medicine in it. Using a placebo helps researchers better understand the effects of the trial medicine.

02

Conditions studied

  • Pain Management
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a bunion and is scheduled to undergo a primary, unilateral bunionectomy that includes distal first metatarsal osteotomy (ie, Austin procedure) with internal fixation
  • Has a (BMI) of 18 to \<40 kg/m\^2
  • Reports moderate or severe pain on the Pain Severity (Verbal Rating Scale) VRS and reports a pain score of ≥4 on the Numeric Pain Rating Scale (NPRS) (Brief Pain Inventory-Short Form [BPI-SF] "Pain Now" Item), within 2 to 9 hours of popliteal block discontinuation
  • Has bunionectomy under regional anesthesia using a Mayo block, popliteal sciatic block and monitored anesthesia care (MAC)

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has any of the following conditions in the index joint:
  • Has a Type 3 deformity requiring a base wedge osteotomy
  • Requires a concomitant surgery such as hammertoe repair or arthrodesis (fusion of the index toe)
  • Has had a prior bunionectomy or other foot surgery on the index foot
  • Has a painful, comorbid condition in the index joint, such as arthritis, that could confound the participant's assessment of postsurgical pain
  • Has an acute or chronic painful physical condition, surgical history, or sensory abnormality that may confound the ability of the participant to assess postoperative pain in the index joint
  • Has a cardiac dysrhythmia (eg, atrial fibrillation), or known structural heart disease (eg, cardiomyopathy)
  • Has a personal history of Brugada syndrome or 2 or more unexplained syncopal events
  • Has a known first degree relative with 2 or more unexplained syncopal events, unexplained cardiac arrest, sudden cardiac death or Brugada syndrome
  • Has a diagnosis of sleep apnea or uses a home continuous positive airway pressure machine
  • Has a history of peptic ulcer disease or gastrointestinal bleeding
  • Has a history of allergy or adverse reaction to opioid(s), acetaminophen (APAP), midazolam, volatile anesthetics, propofol, rocuronium, vecuronium, sugammadex, lidocaine, ondansetron, and/or promethazine
  • Has a history of hepatitis or liver disease that has been active within the 12 months
  • Has a history of , ≤ 3 years prior, except for successfully treated nonmelanoma skin cancer, prostate cancer, or localized carcinoma in situ of the cervix
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    Arm 1: MK-6916 120 milligrams (mg)

    Participants will receive MK-6916 120 mg every 12 hours (q12h) for 48 hours. Participants may receive rescue medication every 6 hours (q6h). Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.

    Drug: MK-6916 · Drug: Rescue Medication

  • Experimental
    Arm 2: MK-6916 70 mg

    Participants will receive MK-6916 70 mg every 12 hours (q12h) for 48 hours. Participants may receive rescue medication every 6 hours (q6h). Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.

    Drug: MK-6916 · Drug: Rescue Medication

  • Active comparator
    Arm 3: hydrocodone 5 mg /acetaminophen 325 mg (HB/APAP)

    Participants will receive hydrocodone 5 mg/acetaminophen 325 mg (HB/APAP) every 6 hours (q6h) for 48 hours. Participants may receive rescue medication q6h. Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.

    Drug: Hydrocodone/acetaminophen (HB/APAP) · Drug: Rescue Medication

  • Placebo comparator
    Arm 4: MK-6916 Placebo

    Participants will receive MK-6916 placebo every 6 hours (q6h). Participants may receive rescue medication q6h for 48 hours. Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.

    Drug: MK-6916 Placebo · Drug: Rescue Medication

Interventions

  • 120 mg or 70 mg oral tablet given every 12 hours (q12h) for 48 hours.

  • DrugHydrocodone/acetaminophen (HB/APAP)

    Hydrocodone 5 mg/acetaminophen 325 mg given as oral capsule every 6 hours (q6h) for 48 hours.

  • DrugMK-6916 Placebo

    Placebo oral table given every 6 hours (q6h) for 48 hours

  • DrugRescue Medication

    Participants requesting rescue medication may receive protocol-specified rescue medication. Rescue treatment consists of open-label oxycodone immediate release (IR) oral tablet 5 mg given every 6 hours (q6h) (given in 5 mg increments for a maximum dose of 10 mg q6h). Participants should be encouraged to wait 1 hour after administration of the first dose of oxycodone 5 mg before administering a second dose. Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.

06

What researchers measure

Primary outcomes

  1. Sum of the Pain Intensity Difference 0 to 48 Hours (SPID48)

    The Sum of the Pain Intensity Difference (SPID) scale quantifies cumulative pain reduction to measure how effectively a pain medication or treatment works over a specific period of time. Pain is assessed by the participant using the Numeric Pain Rating Scale (NPRS) Brief Pain Inventory-Short Form (BPI-SF) "Pain Now" Item, which is a single item questionnaire asking the participant to rate their "pain now" using the numeric rating scale (0= No pain; 10= pain as bad as you can imagine; a higher score indicates more pain). The current pain score is subtracted from the baseline score at regular intervals at which pain is assessed to find the "Pain Intensity Difference". These differences are multiplied by the time interval and added together to yield the SPID. A higher SPID score indicates that a participant experienced more significant, cumulative pain relief during the study window. The least squares (LS) means and standard error will be provided for each treatment group.

    Time frame: Up to approximately 48 hours

Secondary outcomes

  1. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.

    Time frame: Up to approximately 16 days

  2. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 48 hours

  3. Time to ≥2-Point Improvement on the Numeric Pain Rating Scale (NPRS) Brief Pain Inventory-Short Form (BPI-SF) "Pain Now" Single Item Questionnaire

    The NPRS BPI-SF "Pain Now" Item is a single item questionnaire asking the participant to rate their "pain now" using the numeric rating scale (0= No pain; 10= pain as bad as you can imagine; a higer score indicates more pain). Pain is assessed by the participant using the NPRS BPI-SF "Pain Now" Item. Participants are assessed at baseline, and before each dose of study intervention and rescue medication. The time to ≥2-point improvement on the NPRS BPI-SF "Pain Now" Item is defined as the time, in minutes, from baseline to the time to ≥2 point reduction in pain intensity as measured by the NPRS BPI-SF "Pain Now" single item questionnaire, as estimated by the Kaplan-Meier method for each treatment group.

    Time frame: Baseline and up to approximately 48 hours

  4. Total Amount of Opioid Rescue Medication Used (mg) from 0 to 48 Hours

    The total amount of opioid rescue medications used from 0 to 48 hours will be expressed as total milligrams (mg) of opioid rescue medications administered from 0 to 48 hours. Per protocol, the stratified Wilcoxon rank-sum test, stratified by baseline NPRS, will be performed to compare MK-6916 and placebo.

    Time frame: Up to approximately 48 hours

  5. Percentage of Participants who used any Opioid Rescue Medications from 0 to 48 hours

    The percentage of participants who used any opioid rescue medication will be compared between MK-6916 and placebo, using the stratified Miettinen and Nurminen method, with baseline NPRS as the stratification factor.

    Time frame: Up to approximately 48 hours

07

Study locations

9 sites
  • Clinical Pharmacology of Miami ( Site 0718)
    Miami, Florida 33172, United States
    • Study Coordinator · Contact305-817-2900
  • ForCare Clinical Research ( Site 0705)
    Tampa, Florida 33613, United States
    • Study Coordinator · Contact813-264-2155
  • Atlanta Center for Medical Research ( Site 0708)
    Atlanta, Georgia 30331, United States
    • Study Coordinator · Contact404-881-5800
  • Gateway Clinical Trails, Llc ( Site 0701)
    O'Fallon, Illinois 62269, United States
    • Study Coordinator · Contact618-726-1160
  • Legent Orthopedic & Spine Hospital ( Site 0711)
    Bellaire, Texas 77401, United States
    • Study Coordinator · Contact713-367-8548
  • Memorial Hermann Village ( Site 0704)
    Houston, Texas 77043, United States
    • Study Coordinator · Contact281-369-5765
  • Futuro Clinical Trials ( Site 0703)
    McAllen, Texas 78501, United States
    • Study Coordinator · Contact956-999-8399
  • Endeavor Clinical Trials PA ( Site 0700)
    San Antonio, Texas 78240, United States
    • Study Coordinator · Contact210-503-9773
  • JBR Clinical Research ( Site 0702)
    Salt Lake City, Utah 84107, United States
    • Study Coordinator · Contact801-261-2000
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jun 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartEst.
Nov 23, 2026
Primary completionEst.
Jun 10, 2027
CompletionEst.
Jun 10, 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added — first site in United States
Show 9 added (9 United States)
  • Clinical Pharmacology of Miami ( Site 0718) · Miami, United States
  • ForCare Clinical Research ( Site 0705) · Tampa, United States
  • Atlanta Center for Medical Research ( Site 0708) · Atlanta, United States
  • Gateway Clinical Trails, Llc ( Site 0701) · O'Fallon, United States
  • Legent Orthopedic & Spine Hospital ( Site 0711) · Bellaire, United States
  • Memorial Hermann Village ( Site 0704) · Houston, United States
  • Futuro Clinical Trials ( Site 0703) · McAllen, United States
  • Endeavor Clinical Trials PA ( Site 0700) · San Antonio, United States
  • JBR Clinical Research ( Site 0702) · Salt Lake City, United States
Nov 6, 2026
Contact
Study contact now listed: added T•••@merck.com · •••8839. See the current contact
Nov 6, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Nov 6, 2026
    9 sites added — first site in United States
    Show 9 added (9 United States)
    • Clinical Pharmacology of Miami ( Site 0718) · Miami, United States
    • ForCare Clinical Research ( Site 0705) · Tampa, United States
    • Atlanta Center for Medical Research ( Site 0708) · Atlanta, United States
    • Gateway Clinical Trails, Llc ( Site 0701) · O'Fallon, United States
    • Legent Orthopedic & Spine Hospital ( Site 0711) · Bellaire, United States
    • Memorial Hermann Village ( Site 0704) · Houston, United States
    • Futuro Clinical Trials ( Site 0703) · McAllen, United States
    • Endeavor Clinical Trials PA ( Site 0700) · San Antonio, United States
    • JBR Clinical Research ( Site 0702) · Salt Lake City, United States
    Contact Study contact now listed: added T•••@merck.com · •••8839. See the current contact
    + 1 other change: verification date
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862595
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Nov 23, 2026 (estimated)
Primary completion
Jun 10, 2027 (estimated)
Completion
Jun 10, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Toll Free Number
Contact
Trialsites@merck.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-6916

Start the discussion